DUBLIN: The "AI Driven Drug Discovery Patent Landscape Report 2024" report has been added to ResearchAndMarkets.com's offering.

The AI-driven drug discovery report provides a detailed patent landscape analysis, reviewing 1,087 patents from a range of primary jurisdictions, with data from both patent filings and market sales insights. It combines quantitative and qualitative data, offering a reliable data foundation that includes patent applications, technology trends, and market sales growth rates. This multifaceted approach enables a thorough understanding of the current market position, potential growth areas, and emerging technological advancements in AI-driven drug discovery.

The report is divided into key sections, each providing insights into critical aspects of the AI-driven drug discovery industry. The primary sections include the Landscape Overview, Market Analysis, Technology Analysis, and Top Player Analysis, each of which contributes a unique perspective to support strategic decisions in R&D, investment, and competitive positioning.

Landscape Overview

• The landscape overview provides a comprehensive snapshot of the patent landscape within AI-driven drug discovery, tracking patent activity from 2002 to 2024. A clear upward trend in patent filings is observed, with a substantial increase in recent years, indicating accelerated innovation and investment in this field.
• The United States leads with the highest number of patents, followed by China and Europe, emphasizing the global focus and cross-regional competition. The overview section also covers trends in patent ownership, highlighting both established players and emerging entities, which suggests a competitive and evolving field with new entrants continually contributing to AI-driven drug discovery.

Market Analysis Section

• The market analysis section delves into the commercial side of AI-driven drug discovery, focusing on market sales data and projected growth rates. By examining patenting activity alongside market sales data, this section reveals the alignment between technological innovation and market demand.
• The analysis highlights the market's current trajectory and offers insights into potential growth opportunities, emphasizing regions with significant R&D investment. The report's market analysis sheds light on key areas where AI-driven drug discovery is poised for expansion, helping stakeholders understand both current market dynamics and areas with the highest commercial potential.

Technology Analysis Section

• In the technology analysis section, the report reviews core technological domains within AI-driven drug discovery, such as ICT applications for bioinformatics, machine learning for drug development, and biological computing models. Each technology domain is evaluated for its role in advancing drug discovery methods, such as molecule targeting, pattern recognition, and efficacy testing.
• This section identifies leading-edge technologies driving innovation and highlights areas with high patenting activity, signaling where future R&D efforts may concentrate. By examining these specific domains, the technology analysis section equips stakeholders with insights into the technical underpinnings that are shaping the future of AI-driven drug discovery.

Top Player Section

• The top player section offers a closer look at the leading organizations and institutions in the field, such as the University of California, Peptilogics, Genentech, MIT, and Harvard University. Each top player is reviewed based on their patent contributions, strategic focus, and technological developments within AI-driven drug discovery. For example, Peptilogics stands out with its NautilusT AI platform for peptide therapeutics, while Genentech is highlighted for its collaboration with NVIDIA, integrating AI for enhanced molecular design.
• This section also explores collaborations and partnerships among these players, showcasing how strategic alliances are accelerating technological advancements and expanding the scope of AI applications in drug discovery.

The report provides a holistic view of AI-driven drug discovery, from market trends and technological innovations to competitive dynamics. Each section complements the others to create a cohesive narrative on the state and direction of the AI-driven drug discovery industry, making it a valuable resource for decision-makers in R&D, policy, and investment. By integrating patent data, market insights, and a close examination of technology and top players, this report serves as a robust guide for stakeholders aiming to understand and capitalize on this rapidly evolving field.

What You Will Get:

• 90+ Pages PDF Report
• 40+ Pages PDF Slides
• Excel File of each figure including extended data

Key Topics Covered:

1. Key Findings

1.1 Executive Summary

1.2 Introduction

2. Patent Landscape Overview

2.1. Patent Family Analysis

2.2. Patent-Market Coverage

2.3. Geographical Jurisdiction

3. Market and Competitor Analysis

3.1. Market at a Glance

3.2. Market Share of Main Players

3.3. Main Products in AI-Driven Drug Discovery

3.4. Top Applicants

3.5. Market Coverage of Top Applicants

3.6. Top Owners

3.7. Highly-Cited Applicants

3.8. Collaboration

3.8.1. Top Ten Applicants' Collaborations

3.8.2. The Strongest Cooperation Networks

3.9. Top Applicant Activity

3.10. Pioneer Companies in the Last 5 Years

3.11. Top Applicant Clustering

3.12. Pending Patents

4. Technology Analysis

4.1. Top Technologies

4.1.1. Top Technologies by Class

4.1.2. Top Technologies by Sub-Class

4.1.3. Top Technologies by Main-Group

4.1.4. Top Technologies by Sub-Group

4.1.5. Top Technologies and Main Trends

4.2. Five Recent Dominant Technologies

4.3. Key Patents

4.4. Main Themes of Patents

4.5. Technology Clustering

4.6. Top Inventors

5. Key Players' Patent Profile

5.1. California University

5.2. Peptilogics Inc

5.3. Genentech Inc

5.4. Massachusetts Institute of Technology

5.5. Harvard College

Companies mentioned in the report include:

• Peptilogics Inc.
• University of California
• Genentech Inc.
• Insilico Medicine
• Exscientia
• BenevolentAI
• Schrodinger, Inc.
• Atomwise
• Microsoft Corporation (Healthcare & Life Sciences)
• NVIDIA Corporation
• Z Advanced Computing Inc.
• University of Miami
• RowAnalytics Ltd.
• HeartFlow Inc.
• Ginkgo Bioworks
• Reverie Labs
• Accutar Biotechnology
• Evommune
• Novoheart Ltd.
• Chan Zuckerberg Biohub Inc.
• Unity Health Toronto
• EpiAxis Therapeutics
• Orion Biotechnology
• Hoffmann-La Roche
• Berenberg Daniel
• Watkins Andrew Martin
• New York University
• Jecure Therapeutics
• Seragon Pharmaceuticals
• Tanox Inc.

Products/services mentioned in the report include:

• NautilusT AI Platform
• Centaur Chemist
• Pharma.AI
• SPARROW Algorithm
• GRAIL AI Platform
• AtomNet technology

For more information about this report visit https://www.researchandmarkets.com/r/867dqs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Fonte: Business Wire